Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus Erythematosus

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1407-1415

  Von Spee Mayer, Caroline ^a   Siegert, Elise ^a   Abdirama, Dimas ^a   Rose, Angelika ^a   Klaus, Anika ^a   Alexander, Tobias ^a   Enghard, Philipp ^a   Sawitzki, Birgit ^a   Hiepe, Falk ^a   Radbruch, Andreas ^b   Burmester, Gerd Rüdiger ^a   Riemekasten, Gabriela ^a,c   Humrich, Jens Y ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DEFICIENCY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONONUCLEAR CELL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940880014     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207776     Document Type: Article

References (38)

1. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1643-56.
2. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
3. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-87.
4. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
5. Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. JExp Med 2005;201:723-35.
6. Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-51.
7. Sadlack B, Löhler J, Schorle H, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995;25:3053-9.
8. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
9. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21.
10. Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011;10:744-55.
11. Alcocer Varela J, Alarcón Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
12. Lieberman LA, Tsokos GC. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J Biomed Biotechnol 2010;2010:740619.
13. Dauphinee MJ, Kipper SB, Wofsy D, et al. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981;127:2483-7.
14. Wofsy D, Murphy ED, Roths JB, et al. Deficient interleukin 2 activity in Mrl-Mp and C57bl-6j mice bearing the Lpr-gene. J Exp Med 1981;154:1671-80.
15. Humrich JY, Morbach H, Undeutsch R, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci USA 2010;107:204-9.
16. Bonelli M, von Dalwigk K, Savitskaya A, et al. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: A comparative phenotypic analysis. Ann Rheum Dis 2008;67:664-71.
17. Alexander T, Sattler A, Templin L, et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 2013;72:1549-58.
18. Suen JL, Li HT, Jong YJ, et al. Altered homeostasis of CD4+ FoxP3+ regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009;127:196-205.
19. Schoenbrunn A, Frentsch M, Kohler S, et al. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. J Immunol 2012;189:5985-94.
20. Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007;109:365-73.
21. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32.
22. Dwyer KM, Deaglio S, Gao W, et al. CD39 and control of cellular immune responses. Purinergic Signal 2007;3:171-80.
23. Golding A, Hasni S, Illei G, et al. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 2013;65:2898-906.
24. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells. J Immunol 2010;184:3433-41.
25. Linker Israeli M, Bakke AC, Kitridou RC, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983;130:2651-5.
26. Smith KA. Low-dose daily interleukin-2 immunotherapy: Accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS 2001;15:28-35.
27. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26:453-79.
28. Muraguchi A, Kehrl JH, Longo DL, et al. Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med 1985;161:181-97.
29. Crispin JC, Martinez A, Alcocer Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-6.
30. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175:8392-400.
31. Yang HX, Zhang W, Zhao LD, et al. Are CD4+CD25-Foxp3+ cells in untreated newonset lupus patients r egulatory T cells? Arthritis Res Ther 2009;11:R153.
32. Caligiuri MA, Zmuidzinas A, Manley TJ, et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high-affinity receptors. J Exp Med 1990;171:1509-26.
33. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-51.
34. Koreth J, Matsuoka KI, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-66.
35. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77.
36. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013;5:43-79.
37. Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun 2015;58:48-58.
38. Humrich JY, von Spee Mayer C, Siegert E, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis 2015;74:791-2.